Diagnostics News and Research RSS Feed - Diagnostics News and Research

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%. [More]
Using breath tests to diagnose liver diseases: an interview with Larry Cohen

Using breath tests to diagnose liver diseases: an interview with Larry Cohen

It was back in the 1960s that scientists first started to understand that breath could be used to find out different things about diseases and other factors. I’m sure you’re familiar with alcohol breath testing, which was patented back in the ‘50s and has been used since the ‘60s. [More]
BMG Pharma S.R.L Grants The Exclusive Distribution Rights For Gelx® Oral Gel And Gelx® Spray For The Treatment Of Oral Mucositis In Cancer Patients To FERRER INTERNACIONAL S.A.

BMG Pharma S.R.L Grants The Exclusive Distribution Rights For Gelx® Oral Gel And Gelx® Spray For The Treatment Of Oral Mucositis In Cancer Patients To FERRER INTERNACIONAL S.A.

BMG Pharma S.r.l. today is pleased to announce that it has signed an exclusive distribution agreement with FERRER INTERNACIONAL S.A., granting them the rights to promote, sell and market its own product GelX for the Middle East, Eastern Europe, Russia and North Africa. [More]
Mobile diagnosis device to help reduce unnecessary antibiotics prescribing

Mobile diagnosis device to help reduce unnecessary antibiotics prescribing

New biosensor-based technology could help to reduce the over-prescribing of antibiotics by giving GPs and other frontline healthcare staff an accurate and fast method of identifying the nature of infectious diseases. [More]
Signostics gets FDA 510k clearance for handheld bladder scanner

Signostics gets FDA 510k clearance for handheld bladder scanner

Medical device company, Signostics, announced today it has clearance from the U.S. Food and Drug Administration to launch the SignosRT Bladder, the company’s new hand-held bladder scanner. [More]

YODA Project announces availability of clinical trial data for medical devices

The Yale University Open Data Access (YODA) Project is announcing the first-ever broad availability of clinical trial data for medical devices and diagnostics by a company. This historic expansion of data sharing is made possible through collaboration with Johnson & Johnson. [More]
Ultraspecific and extensively validated monoclonal antibodies now available from AMSBIO

Ultraspecific and extensively validated monoclonal antibodies now available from AMSBIO

AMSBIO has announced the availability of ultraspecific and extensively validated monoclonal antibodies under the UltraMAB™ brand. [More]
Sophia Genetics obtains CE-IVD marking for BRCA1/2 testing solution

Sophia Genetics obtains CE-IVD marking for BRCA1/2 testing solution

Sophia Genetics, the European leader in Data Driven Medicine, has today obtained CE-IVD marking for its solution to detect BRCA1/2 associated genetic variants in live tumours. [More]
Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies. [More]

Beckman Coulter Life Sciences expands range of Avanti High Performance centrifuges

Beckman Coulter Life Sciences continues to expand its range of Avanti High Performance centrifuges with the launch of the Avanti JXN-30. This capitalizes on the company’s unique expertise in ultracentrifugation by incorporating features from its top of the line Optima X Series into the High Performance Avanti JXN-30. [More]
BioLight invests in newly-formed ophthalmic company

BioLight invests in newly-formed ophthalmic company

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced its investment in a newly-formed ophthalmic company that has licensed-in a world-wide drug-delivery platform from the Hebrew University, Israel, that has the potential to enable more efficient and safer delivery of eye drops. [More]
HLI gains access to PGDx's cancer genomics solutions to expand cancer genome analysis

HLI gains access to PGDx's cancer genomics solutions to expand cancer genome analysis

Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, and Human Longevity, Inc., the human health information technology and health care company, today announced that HLI will have access to PGDx's cancer genomics solutions to expand its analysis of cancer genomes, including CancerSelect, PlasmaSelect, CancerXome, METDetect and CancerComplete. [More]
QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

QIAGEN announced today the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating nucleic acids obtained from blood samples to assess an important genomic mutation in patients with non-small cell lung cancer (NSCLC), the most common form of this cancer. [More]

Alere completes sale of Alere Health

Alere Inc. today announced the completion of the previously announced sale of Alere Health and its subsidiaries, which provide leading condition management, case management, wellbeing, wellness and women's and children's health services to regional and local health plans, Fortune 500 employers and state governments, to Optum for $600 million in cash. [More]
DiaCarta raises $8 million in Series A financing from BVCF

DiaCarta raises $8 million in Series A financing from BVCF

DiaCarta, Inc., a privately-held biotechnology company raised $8 million in Series A financing from BVCF (BioVeda China Fund). Proceeds from Series A financing will be used to expand the product portfolio and support global commercialization. Dr. Weixin Xu of BVCF will join DiaCarta board of directors. [More]
Exposure to nanoparticles can play major role in development of cardiovascular diseases

Exposure to nanoparticles can play major role in development of cardiovascular diseases

Nanoparticles, extremely tiny particles measured in billionths of a meter, are increasingly everywhere, and especially in biomedical products. Their toxicity has been researched in general terms, but now a team of Israeli scientists has for the first time found that exposure nanoparticles (NPs) of silicon dioxide (SiO2) can play a major role in the development of cardiovascular diseases when the NP cross tissue and cellular barriers and also find their way into the circulatory system. [More]
Proteomics market expected to experience continual growth

Proteomics market expected to experience continual growth

The market for microarrays used to study the workings of proteins are in great demand, according to Kalorama Information. The healthcare market research publisher said "proteomics" instruments, reagents and testing are needed to discover new biomarkers and even new drugs, and that the market for them topped 5 billion dollars in 2013. [More]
Researchers develop mobile suitcase laboratory to detect Ebola virus

Researchers develop mobile suitcase laboratory to detect Ebola virus

No electricity, no reliable cold chain, no diagnostic equipment available - scientists in field laboratories who diagnose and deal with Ebola infections often work under challenging conditions. Researchers at the DPZ have developed Diagnostics-in-a-Suitcase, which contains all reagents and equipment to detect the Ebola virus within 15 minutes at point-of-need. [More]
Debiopharm receives FDA Fast Track designation for anti-infectious agent Debio 1450

Debiopharm receives FDA Fast Track designation for anti-infectious agent Debio 1450

Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced that the US Food and Drug Administration granted Fast Track designation to its anti-infectious agent Debio 1450, a highly potent antibiotic specifically active against all Staphylococcus species. [More]
New guidance recommends use of primary HPV test for cervical cancer screening

New guidance recommends use of primary HPV test for cervical cancer screening

About 80 million U.S. women ages 25 to 65 should be screened periodically by their health care providers for cervical cancer. At present, the standard way to do that is a Pap smear alone, or co-testing using both a Pap smear and a human papillomavirus (HPV) test. [More]